AASLD 2015

3D Regimen Sustains SVR Rates through Week 48 in HCV GT1

The 3 direct-acting antiviral (3D) regimen of ombitasvir, paritaprevir (boosted with ritonavir), and dasabuvir, with or without ribavirin, demonstrated long-term efficacy in a broad population of patients with hepatitis C virus (HCV) infected with genotype (GT) 1, results from six Phase 3 studies reported at The Liver Meeting® 2015.